T. Yeh

发表

Inhibition of Growth Factor Signaling by Small-Molecule Inhibitors of ErbB, Raf,and MEK

Ellen R. Laird, E. Laird, J. Lyssikatos, 2006 .

Progress towards therapeutic small molecule MEK inhibitors for use in cancer therapy.

J. Lyssikatos, K. Koch, J. Winkler, 2005, Current topics in medicinal chemistry.

The proteasome inhibitor PS-341 overcomes TRAIL resistance in Bax and caspase 9-negative or Bcl-xL overexpressing cells

W. Zong, C. Thompson, A. Kraft, 2003, Oncogene.

Potent and selective mitogen-activated protein kinase kinase (MEK) 1,2 inhibitors. 1. 4-(4-bromo-2-fluorophenylamino)-1- methylpyridin-2(1H)-ones.

J. Lyssikatos, K. Koch, R. Woessner, 2006, Journal of medicinal chemistry.

Insulin Receptor Signaling in Madin-Darby Canine Kidney Cells Overexpressing the Human Insulin Receptor

R. Roth, T. Yeh, T. Yeh, 1994, Diabetes.

Biological Characterization of ARRY-142886 (AZD6244), a Potent, Highly Selective Mitogen-Activated Protein Kinase Kinase 1/2 Inhibitor

Vivienne Marsh, S. Gross, B. Brandhuber, 2007, Clinical Cancer Research.

Efficacy, safety and tolerability of MEDI4736 (durvalumab [D]), a human IgG1 anti‐programmed cell death‐ligand‐1 (PD‐L1) antibody, combined with gefitinib (G): A phase I expansion in TKI‐naïve patients (pts) with EGFR mutant NSCLC: 57O

Haiyi Jiang, D. Gibbons, L. Chow, 2016, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Safety and tolerability results from a phase I study of MEDI4736, a human IgG1 anti-programmed cell death-ligand-1 (PD-L1) antibody, combined with gefitinib in patients (pts) with non-small-cell lung cancer (NSCLC).

D. Gibbons, Dong-Wan Kim, L. Chow, 2015 .

A Phase 1 study of gefitinib combined with durvalumab in EGFR TKI-naive patients with EGFR mutation-positive locally advanced/metastatic non-small-cell lung cancer

D. Gibbons, M. Roudier, Dong-Wan Kim, 2020, British Journal of Cancer.

Disruption of a putative SH3 domain and the proline‐rich motifs in the 53‐kDa substrate of the insulin receptor kinase does not alter its subcellular localization or ability to serve as a substrate

R. Roth, T. Yeh, G. Keller, 1998, Journal of cellular biochemistry.

Characterization and Cloning of a 58/53-kDa Substrate of the Insulin Receptor Tyrosine Kinase (*)

R. Roth, A. Danielsen, T. Yeh, 1996, The Journal of Biological Chemistry.

Discovery of MK-4688: an Efficient Inhibitor of the HDM2-p53 Protein-Protein Interaction.

G. Scapin, M. Altman, X. Fradera, 2021, Journal of medicinal chemistry.

AZD5153: A Novel Bivalent BET Bromodomain Inhibitor Highly Active against Hematologic Malignancies

G. Mills, A. Dulak, A. Rabow, 2016, Molecular Cancer Therapeutics.

Identification of CCR2 and CD180 as Robust Pharmacodynamic Tumor and Blood Biomarkers for Clinical Use with BRD4/BET Inhibitors

Greg O'Connor, J Carl Barrett, A. Dulak, 2017, Clinical Cancer Research.

Abstract 2515: Preclinical Development of ARRY-162, A Potent and Selective MEK 1/2 Inhibitor

S. Gross, J. Lyssikatos, K. Koch, 2010 .

Preclinical development of ARRY-142886, a potent and selective MEK inhibitor

S. Gross, B. Brandhuber, T. Morales, 2004 .

342 Anti-tumor activity, pharmacokinetic and pharmacodynamic effects of the MEK inhibitor ARRY-142886 (AZD6244) in a BxPC3 pancreatic tumor xenograft model

J. Lyssikatos, J. Winkler, S. Eckhardt, 2004 .

368 Demonstration of broad in vivo anti-tumor activity of ARRY-142886 (AZD-6244), a potent and selective MEK inhibitor

S. Cartlidge, R. Woessner, T. Klinowska, 2004 .

Phase I study of gefitinib (G) + durvalumab (D) for locally advanced/metastatic non-small cell lung cancer (NSCLC) harbouring epidermal growth factor receptor (EGFR) sensitising mutations.

D. Gibbons, M. Roudier, M. Marotti, 2019, Annals of oncology : official journal of the European Society for Medical Oncology.